Quantitative proteomics analysis of differentially expressed proteins in activated B-cell-like diffuse large B-cell...

Area of Science:

• * Hematology
• * Oncology
• * Proteomics

Background:

• * Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma (NHL) with varied outcomes.
• * Activated B-cell-like DLBCL (ABC-DLBCL) is a subtype with unclear pathogenesis.
• * Current treatments cure half of DLBCL cases, but one-third relapse.

Purpose of the Study:

• * To investigate differentially expressed proteins in ABC-DLBCL using iTRAQ quantitative proteomics.
• * To identify novel protein biomarkers associated with ABC-DLBCL development.
• * To provide insights into the molecular mechanisms driving ABC-DLBCL.

Main Methods:

• * Quantitative proteomics (iTRAQ) was employed on 7 ABC-DLBCL samples and 8 control lymph node samples.
• * Protein-protein interaction (PPI) network analysis, Gene Ontology (GO), and KEGG pathway analysis were performed.
• * Validation of six key proteins (HSP90AB1, GNA13, LAMB2, LAMA5, YWHAZ, IKBKB) using PRM and TCGA data.

Main Results:

• * A total of 5974 proteins were identified.
• * 131 proteins were upregulated and 204 were downregulated in ABC-DLBCL compared to controls (P < 0.05, fold change > 1.2).
• * Expression levels of six target proteins were significantly different between groups, validating iTRAQ findings.

Conclusions:

• * This study is the first to use iTRAQ technology to identify proteins associated with ABC-DLBCL.
• * The identified proteins and pathways offer new perspectives on ABC-DLBCL pathogenesis.
• * Targeting these proteins may improve treatment strategies and reduce mortality in DLBCL patients.
• * Further research is needed to elucidate the functional roles of these proteins in ABC-DLBCL.